Investor Area

Home / Investor Area / Nomura Update “F12 – good progress, expect a F13 EMA decision”

Nomura Update “F12 – good progress, expect a F13 EMA decision”

Vitiligo market is underserved in our view – CUV’s potential product addresses this.